Results 171 to 180 of about 1,354,772 (332)

Bridging mechanism and design: modern medicinal chemistry approaches to thymidylate synthase inhibitors. [PDF]

RSC Adv
Al-Karmalawy AA, Eissa ME, Yousef TA, Al Khatib AO, Hawas SS.   +4 more
europepmc   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Stick to the beads: supercharging medicinal chemistry and methodology development with ChemBeads. [PDF]

RSC Med Chem
Tu NP, Wang Y.
europepmc   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source

Remarkable Potential of the α-Aminophosphonate/Phosphinate Structural Motif in Medicinal Chemistry

, 2011
Artur Mucha, Paweł Kafarski, Łukasz Berlicki   +2 more
openalex   +1 more source

Imidazo[1,2‑<i>a</i>]pyridines in Medicinal Chemistry: Recent Advances in Synthesis and Biological Activities. [PDF]

ACS Omega
Ferreira LAP, Caruso L, Nadur NF, Franco DP, Sousa GLS, Lacerda RB, Kümmerle AE.   +6 more
europepmc   +1 more source

TREX1, a predator for treating MSI‐H tumors?

Molecular Oncology, EarlyView.
Immunotherapy benefits many patients; yet, some with MSI‐H tumors remain unresponsive despite their high immunogenicity. Xu et al. reveal that TREX1 enables immune evasion by degrading cytosolic DNA and suppressing cGAS–STING–IFN‐I signaling. TREX1 loss restores DNA sensing, increases CD8+ T and NK cell infiltration, and boosts antitumor immunity ...
Elena Benidovskaya, Joséphine Deneft, Marc Van den Eynde   +2 more
wiley   +1 more source

Medicinal Chemistry: Abstracts 280-357

CHIMIA, 2012
doaj   +1 more source

Hungarian–German–Italian–Polish Joint Meeting on Medicinal Chemistry, 2–6 September 2001, Budapest, Hungary [PDF]

, 2001

openalex   +1 more source

Recent Insights in Multi-Target Drugs in Pharmacology and Medicinal Chemistry. [PDF]

ChemMedChem
Cemali SH, Poyraz S, Belveren S, Taş S, Tamer MA, Döndaş NY, Döndaş HA, Sansano JM.   +7 more
europepmc   +1 more source